Melarsoprol

Melarsoprol

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	?
Routes of administration	IV
ATC code	P01CD01 (WHO) Template:ATCvet
Legal status
Legal status	?
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Elimination half-life	35 hours
Excretion	Renal
Identifiers
IUPAC name (2-(4-(4,6-diamino-1,3,5-triazin-2-ylamino)phenyl)- 1,3,2-dithiarsolan-4-yl)methanol
CAS Number	494-79-1 N
PubChem CID	10311
ChemSpider	9889 Y
UNII	ZF3786Q2E8
KEGG	D00832 Y
ChEMBL	ChEMBL166 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C12H15AsN6OS2
Molar mass	398.341 g/mol
3D model (JSmol)	Interactive image
SMILES OCC1S[As](SC1)c3ccc(Nc2nc(nc(n2)N)N)cc3
InChI InChI=1S/C12H15AsN6OS2/c14-10-17-11(15)19-12(18-10)16-8-3-1-7(2-4-8)13-21-6-9(5-20)22-13/h1-4,9,20H,5-6H2,(H5,14,15,16,17,18,19) Y Key:JCYZMTMYPZHVBF-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Melarsoprol
Articles
Most recent articles on Melarsoprol Most cited articles on Melarsoprol Review articles on Melarsoprol Articles on Melarsoprol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Melarsoprol Images of Melarsoprol Photos of Melarsoprol Podcasts & MP3s on Melarsoprol Videos on Melarsoprol
Evidence Based Medicine
Cochrane Collaboration on Melarsoprol Bandolier on Melarsoprol TRIP on Melarsoprol
Clinical Trials
Ongoing Trials on Melarsoprol at Clinical Trials.gov Trial results on Melarsoprol Clinical Trials on Melarsoprol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Melarsoprol NICE Guidance on Melarsoprol NHS PRODIGY Guidance FDA on Melarsoprol CDC on Melarsoprol
Books
Books on Melarsoprol
News
Melarsoprol in the news Be alerted to news on Melarsoprol News trends on Melarsoprol
Commentary
Blogs on Melarsoprol
Definitions
Definitions of Melarsoprol
Patient Resources / Community
Patient resources on Melarsoprol Discussion groups on Melarsoprol Patient Handouts on Melarsoprol Directions to Hospitals Treating Melarsoprol Risk calculators and risk factors for Melarsoprol
Healthcare Provider Resources
Symptoms of Melarsoprol Causes & Risk Factors for Melarsoprol Diagnostic studies for Melarsoprol Treatment of Melarsoprol
Continuing Medical Education (CME)
CME Programs on Melarsoprol
International
Melarsoprol en Espanol Melarsoprol en Francais
Business
Melarsoprol in the Marketplace Patents on Melarsoprol
Experimental / Informatics
List of terms related to Melarsoprol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Melarsoprol (INN) is a prodrug used in the treatment of East African (rhodesiense) human African trypanosomiasis. It is produced by Sanofi-Aventis and is on the World Health Organization's List of Essential Medicines.

Freidheim demonstrated in 1949 the effects of melarsoprol against late-state trypanosomiasis. Melarsoprol is the dimercaptopropanol derivative of melarsen oxide (Mel Ox), whose structure is shown below:

The main drug prescribed is Mel B, however, an alarming number of side effects occur from treatment. The active metabolite of Mel B is Mel Ox, which is taken up by the TbAT1 adenosine transporter in T. brucei brucei. Due to side effects similar to arsenic poisoning, other pharmacological agents have become first-line treatments for stage one of the disease and for certain trypanosomes.

Treatment

All people with confirmed trypanosome-caused disease must be treated. Treatment differs based on whether disease levels are considered stage 1 or stage 2 and based on which specific trypanosome has infected a patient. Below are treatment options (all adapted from ).

Melasarprol is used in the treatment of the second stage of the disease, and is the only treatment available for late-stage T. b. rhodesiense treatment.

Mechanism of action

Melarsoprol is a prodrug, which is metabolized to melarsen oxide (Mel Ox) as its active form. Mel Ox is an arsen-oxide which irreversibly binds to vicinal sulfhydryl groups causing the inactivation of enzymes. The inability to distinguish between host and parasites renders this drug highly toxic with many side effects.

Mel Ox reacts with trypanothione (a spermidine-glutathione adduct which replaces glutathione in trypanosomes). Binding to this adduct forms a melarsen oxide-trypanothione adduct (Mel T) which competitively inhibits trypanothione reductase, effectively killing the parasitic cell.

Dosage

Two arsenic-containing stereoisomers exist in a 3:1 molar ratio. As melarsarprol is insoluble in water, dosage occurs via a 3.6% propylene glycol intravenous injection.

Pharmacokinetics

The half-life of melarsoprol is less than 1 hour, but bioassays indicate a 35-hour half-life. This is indicative of pharmacologic agents with active metabolites. One such metabolite, Mel Ox, reaches maximum plasma levels about 15 minutes after melarsoprol injection. Clearance is at 21.5 ml/min/kg and Mel Ox half-life is 3.9 hours.

Failure Rates & Resistance

Failure rates of 20-27% in certain African countries have been reported. These are linked to both drug resistance and other mechanisms which have not yet been elucidated. Resistance is likely due to transport problems associated with the P2 transporter, an adenine-adenosine transporter. Resistance can occur with point mutations within this transporter.

Therapeutic uses

Due to high toxicity, melarsarprol is reserved only for the most dangerous of cases - stage 2 infection. Other agents with lower toxicity are used in stage 1. The 2009 approval of nifurtimoxeflornithine combination therapy (NECT) for the treatment of T. b. gambiense served to limit merlarsoprol to the treatment of second-stage T. b. rhodesiense solely.

Side effects

Being a toxic organic compound of arsenic, melarsoprol is a highly dangerous treatment which is only administered by injection under the supervision of a physician, as it can produce similar effects as arsenic poisoning. Among clinicians, it is colloquially referred to as "arsenic in antifreeze". It is known to cause a range of side effects including convulsions, fever, loss of consciousness, rashes, bloody stools, nausea, and vomiting. It causes encephalopathy in 5–10% of cases, of which 40% die.